IL18 and non-Hodgkin lymphoma: A phase 1 study showed that the combination of ofatumumab with IL-18 in 9 patients with NHL (7 DLBCL) post high dose chemotherapy and PBSCT is feasible and tolerable with no dose limiting toxicities.